BiotechTube
Pax Neuroscience

Pax Neuroscience

San Diego, United States· Est.
paxneuroscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Pax Neuroscience is a private, pre-revenue diagnostics company targeting the massive and underserved depression market. Its core asset is the MoodMark® platform, a biomarker-based assay that measures Gsalpha protein localization in blood cells to provide objective diagnostic and treatment response data. The company has secured approximately $1.8 million in non-dilutive funding from the National Institute of Mental Health (NIMH) via SBIR/STTR grants to validate its technology. Pax aims to serve both clinical depression management and pharmaceutical R&D, addressing a critical need for precision in psychiatric care.

PsychiatryMajor Depressive Disorder

Technology Platform

MoodMark® platform: A biomarker assay measuring Gsalpha protein localization in lipid raft vs. non-raft fractions of blood cell membranes to objectively diagnose depression and predict antidepressant treatment response.

Funding History

2
Total raised:$4.5M
Grant$500K
Seed$4M

Opportunities

The massive, underserved global depression market craves objective tools to move away from subjective, trial-and-error care.
Success could enable precision psychiatry, dramatically improving patient outcomes and reducing healthcare costs.
The platform also offers a high-value tool for pharmaceutical companies to de-risk and accelerate antidepressant drug development.

Risk Factors

Key risks include the failure of the biomarker to validate in larger clinical studies, the significant challenges of obtaining regulatory clearance and insurance reimbursement for a novel psychiatric diagnostic, and the difficulty of changing established clinical practice patterns in psychiatry.

Competitive Landscape

The competitive landscape for objective depression diagnostics is emerging but fragmented. Potential competitors include companies developing EEG-based biomarkers (e.g., Magnus Medical), genetic tests (e.g., GeneSight), or other blood-based assays. Pax's specific focus on the Gsalpha translocation mechanism could provide a differentiated approach, but it must prove superior clinical utility to gain market share.

More companies in Diagnostics & Precision Medicine →More companies in United States →